Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Two different teams from the Medical Sciences Division have received a share of $14 million in funding from the Chan Zuckerberg Initiative as one of 29 projects that will explore emerging ideas regarding the role of inflammation in disease.

None

 

Two different teams from across Medical Sciences have been awarded a grant from the Chan Zuckerberg Initiative.

Associate Professor Mathilda Mommersteeg, Professor Paul Riley,and Professor Robin Choudhury will use their award to perform single cell analysis of inflammation during heart regeneration. Professor Mark Coles, Dr Calliope Dendrou, and Dr Anita Milicic will combine their expertise to create the first map of adjuvant-induced inflammation on tissues from diverse ethnic groups and build a unique resource that will inform more inclusive global vaccine design and development.

While inflammation is a natural defense that helps our bodies maintain a healthy state, chronic inflammation results in harmful diseases such as asthma, arthritis, and heart disease, and can also play a role in organ failure, neurodegenerative diseases like Alzheimer's, and many other conditions such as COVID-19.

The CZI welcomed 80 researchers to work on the two-year pilot projects, 75 percent of which are led by early-career scientists within six years of starting their independent position. Grantee teams are made up of two to three investigators with distinct areas of expertise and they represent 11 countries. 

Read full stories

Professor Mark Coles, Dr Calliope Dendrou, and Dr Anita Milicic research is explained in full on their departmental websites:

- The Jenner Institute

- The Wellcome Centre for Human Genetics

- Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences

Associate Professor Mathilda Mommersteeg, Professor Paul Riley,and Professor Robin Choudhury research is explained more fully here:

- Department of Physiology, Anatomy and Genetics

Similar stories

Oxford vaccine reaches one billion doses released

The University of Oxford’s and our partners AstraZeneca have today announced that one billion doses of the ChAdOx1 nCov-19 coronavirus vaccine have been released, to more than 170 countries, marking a key milestone as part of the University and AstraZeneca’s joint vision to make the available to the world, on a not-for-profit basis for the world during the pandemic, and in perpetuity for low- and middle-income countries.

Research programme tackling COVID-19 variants of concern receives funding boost

A gift from the Red Avenue Foundation will enable the expansion of a major research programme aimed at rapidly identifying and interrogating emerging COVID-19 variants.

Phase I trial begins of new vaccine against the Plague

Researchers at the University of Oxford today launched a Phase 1 trial to test a new vaccine against plague.

New therapeutic targets identified in the treatment of psoriatic arthritis

Researchers identify two inflammatory-driving proteins, osteopontin and CCL2, highly expressed in psoriatic arthritis joints.

Treatment choice for rotator cuff disorders could create efficiency and savings for the NHS

A trial that evaluated the clinical and cost effectiveness of physiotherapy treatments for rotator cuff disorders suggests cost savings can be made while maintaining positive patient outcomes.